Our Market
Cardiovascular disease is the number one killer in the United States. According to the American Heart Association (AHA Heart Disease & Stroke Statistics, 2010 Update), it was estimated that approximately 81,100,000 Americans had one or more forms of cardiovascular disease (CVD).  This number is expected to rise as the population continues to age adding increased cost pressure

Read more...

Employment Opportunities
VectraCor is FDA approved and CE Mark Registered for the VectraplexECG System. We have immediate opportunities for independent representatives and distributors to sell its disruptive products in the United States and Worldwide.  If you are interested in an Exclusive Territory, please use the above "Contact Us" button and send your information or call: 973-904-0444

Join Our Team...

VectraCor Read about our patented tech to help identify heart attacks more quickly. 5 electrodes=15-lead ECG #heartattack #ami http://t.co/aBz9yv4WOA
VectraCor VectraCor will be exhibiting @ the Society for Cardiovascular Patient Care #SCPC booth28.San Antonio Marriott River Center May5-7 #chestpain

Breaking News

VectraCor Inc., Maker of Novel Cardiac Technologies, Acquires QRS Diagnostic

Totowa, NJ and Maple Grove, MN - December 12, 2014 – VectraCor Inc., a medical device company with a novel cardiac electrical biomarker called the CEB®, and QRS Diagnostic , a healthcare technology and medical supplies provider, announced that they have entered into a definitive agreement under which VectraCor has agreed to acquire QRS Diagnostic. The deal was closed December 12th 2014. Following this closing, the company will do business as QRS Diagnostic - A VectraCor Company. VectraCor Inc. will retain staff and an office in Minnesota, while moving some functions to New Jersey.

 

Read Full Press Release